Piper Sandler Raises Compass Therapeutics (NASDAQ:CMPX) Price Target to $6.00

Compass Therapeutics (NASDAQ:CMPX) had its target price increased by investment analysts at Piper Sandler from $4.00 to $6.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price points to a potential upside of 179.72% from the stock’s previous close.

A number of other research analysts also recently commented on the stock. Canaccord Genuity Group lowered their price objective on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, April 28th. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Citizens Jmp reiterated a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 28th. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. Finally, Wall Street Zen downgraded shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $11.77.

Compass Therapeutics Stock Up 7.8%

Compass Therapeutics stock traded up $0.15 during mid-day trading on Friday, hitting $2.15. The company’s stock had a trading volume of 2,131,049 shares, compared to its average volume of 4,718,508. The stock’s fifty day moving average price is $2.10 and its two-hundred day moving average price is $3.88. The stock has a market capitalization of $386.29 million, a P/E ratio of -5.21 and a beta of 0.92. Compass Therapeutics has a twelve month low of $1.61 and a twelve month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Equities analysts expect that Compass Therapeutics will post -0.42 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Simplicity Wealth LLC acquired a new position in Compass Therapeutics in the 2nd quarter valued at approximately $80,000. Bank of New York Mellon Corp bought a new stake in shares of Compass Therapeutics in the 2nd quarter worth approximately $769,000. State of Wyoming acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $31,000. GSA Capital Partners LLP acquired a new stake in shares of Compass Therapeutics during the 2nd quarter worth approximately $154,000. Finally, Walleye Trading LLC bought a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $55,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.